Premium
Effects of midazolam on small bowel motility in humans
Author(s) -
Maria Castedal,
Einar Björnsson,
Hasse Abrahamsson
Publication year - 2000
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2000.00741.x
Subject(s) - midazolam , duodenum , migrating motor complex , placebo , motility , medicine , intestinal motility , bolus (digestion) , anesthesia , gastroenterology , biology , pathology , alternative medicine , sedation , genetics
Background: Benzodiazepines are used as sedatives for some intestinal procedures and as hypnotics, and this is the reason for studying their effects on duodenojejunal motility. Methods: Antroduodenojejunal manometry was performed in 13 healthy volunteers on two different occasions, when placebo or midazolam were given intravenously (randomized, double‐blind). A bolus dose of midazolam 0.03 mg/kg was followed by 0.015 mg/kg after 1.5, 3 and 4.5 h. After 5 h observation of interdigestive motility, the volunteers were given a test meal and recording continued for another hour. Twenty‐eight motility variables were compared. Results: With midazolam the median motility index of phase III in the proximal duodenum was increased by 37% ( P < 0.05), which was a consequence of both a longer duration ( P < 0.01) and higher pressure amplitudes ( P < 0.05), compared with placebo. A longer duration (9%) of phase III was also seen in the distal duodenum ( P < 0.05). With midazolam the duration of the migrating motor complex was shortened by 27% ( P < 0.05). No statistically significant difference was found for the number of episodes of phase III registered ( P =0.09), or for the other 22 motility variables compared including the duodenal retroperistalsis in late phase III. Conclusion: Midazolam does affect some aspects of duodenal motility, especially in the proximal part, but phase III‐related retroperistalsis is not affected.